PT - JOURNAL ARTICLE AU - Devang Parikh AU - Alok Chaturvedi AU - Naman Shah AU - Piyush Patel AU - Ronak Patel AU - Suma Ray TI - Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial AID - 10.1101/2021.07.26.21261119 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.26.21261119 4099 - http://medrxiv.org/content/early/2021/07/27/2021.07.26.21261119.short 4100 - http://medrxiv.org/content/early/2021/07/27/2021.07.26.21261119.full AB - Background COVID-19 hyper-immune globulin (HIG) solution is a human plasma-derived, highly-purified, concentrated, virus-inactivated preparation of neutralizing antibodies (NAbs) against COVID-19.Methods This was a randomized, two-arm, controlled, multi-center trial to evaluate the efficacy and safety of COVID-19 HIG in patients who were hospitalized with moderate-severe COVID-19 infection.Results A total of 60 patients were randomized (30 in each arm). Overall, COVID-19 HIG was well-tolerated without any serious treatment-emergent adverse event or tolerability issue. The mean change in ordinal scale by day 8 was 1.7±1.61 in the test arm vs. 2.0±1.68 in the control arm (mITT; p=0.367). Early and high NAbs were observed in the test arm compared to the control arm.More patients had negative RT-PCR by day 3 for the test arm vs. the control arm (mITT: 46.67% in test vs. 37.93% in control). The median time to be RT-PCR negative was 5.5 days for the test arm vs. 8.0 days for the control arm for PP population. Patients receiving COVID-19 HIG showed early improvement (reduction) in the biomarkers (CRP, IL-6, and D-dimer).Conclusion COVID-19 HIG was found to be safe and well-tolerated. Early and high NAbs were achieved in COVID-19 HIG recipients qualifying the product as a suitable treatment option, particularly in an immunocompromised state. It should be given early in infection to mitigate progression to severe disease. It should be evaluated for post-exposure prophylaxis as well as for prevention (where a vaccine is not suitable or effective). It should be evaluated in the pediatric population as well.Competing Interest StatementThis trial was sponsored and funded by Intas Pharmaceuticals Ltd., India. DP, AC, PP, and SR are employees of Intas Pharmaceuticals Ltd. NS and RP are employees of Lambda Therapeutics Research Ltd. The authors declare no other potential conflicts of interest.Clinical TrialCTRI/2020/09/027903Funding StatementThis trial was sponsored and funded by Intas Pharmaceuticals Ltd., India.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the International Conference on Harmonisation Guidance for Good Clinical Practice guidelines and all applicable local regulatory requirements. The study was approved by the Central Licensing Authority, Directorate General of Health Services, India. The approval was also obtained from the ethics committees of all the participating study sites: Care Institute of Medical Sciences, Ahmedabad, India; Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, India; Adichunchanagiri institute of medical Sciences, Mandya, India; Centre for Research SRV Hospital, Mumbai, India; Sri Ramachandra Institute of Higher Education & Research, Chennai, India; Government Medical College, Nagpur, India; and Gujarat Medical Education & Research Society Gotri Medical College, Vadodara, India. Participants provided written informed consent before any study-related procedures were performed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary material.